Skip to main content
55°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
AstraZeneca PLC - American Depositary Shares
(NQ:
AZN
)
71.93
-0.90 (-1.24%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AstraZeneca PLC - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
Synchronicity: Denying The Unexplainable
February 24, 2025
Elon Musk and Neurolinks has been loud about the singularity—AI surpassing human intelligence. But has curiosity has lost its oomph?
Via
Talk Markets
Topics
Stocks / Equities
3 Magnificent Growth Stocks to Buy Right Now
February 22, 2025
Via
The Motley Fool
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
February 21, 2025
From
Faruqi & Faruqi, LLP
Via
Business Wire
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
February 20, 2025
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent.
Via
Benzinga
What's a Good Price for AstraZeneca Stock?
February 19, 2025
Via
The Motley Fool
How Is The Market Feeling About AstraZeneca?
February 17, 2025
Via
Benzinga
Is NASDAQ:AZN suited for quality investing?
February 14, 2025
A fundamental analysis of (NASDAQ:AZN): Is ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) a Strong Candidate for Quality Investing?
Via
Chartmill
Why AstraZeneca Topped the Market on Thursday
February 06, 2025
Via
The Motley Fool
AZN Deadline: Rosen Law Firm Encourages AstraZeneca PLC Investors to Secure Counsel Before Important February 21 Deadline in Securities Class Action First Filed by the Firm – AZN
February 19, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Big Money Is Betting On Europe, Should You? 3 ETFs To Watch
February 19, 2025
European fund managers are bullish on stocks, with 3 top ETFs to consider: SPDR EURO STOXX 50 (FEZ), Vanguard FTSE Europe (VGK), Xtrackers MSCI EAFE Hedged Equity (DBEF)
Via
Benzinga
Topics
ETFs
George Soros Makes Fresh Bets On Alphabet, Small Caps: What About SPY Puts And Alibaba?
February 19, 2025
Soros Fund Management made bullish bets on Alphabet and small-cap stocks while reducing exposure to SPY and Chinese tech in Q4.
Via
Benzinga
Deadline Soon: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
February 19, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
AstraZeneca Unusual Options Activity
February 06, 2025
Via
Benzinga
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
February 18, 2025
Via
Benzinga
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
February 15, 2025
Via
The Motley Fool
AstraZeneca's Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients
February 14, 2025
AstraZeneca's Imfinzi perioperative regimen improved survival outcomes in muscle-invasive bladder cancer, with FDA Priority Review expected in Q2 2025.
Via
Benzinga
Exposures
Product Safety
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
February 14, 2025
From
AstraZeneca
Via
Business Wire
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
February 13, 2025
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.
Via
Benzinga
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
February 13, 2025
Via
Benzinga
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
February 12, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Trade Desk, Leidos, Devon Energy And A Major Health Care Stock On CNBC's 'Final Trades'
February 12, 2025
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 11, 2025
Via
Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm
February 10, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm
February 07, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
AstraZeneca Plc (AZN) Q4 2024 Earnings Call Transcript
February 06, 2025
AZN earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
AstraZeneca Bounds Higher On Fourth-Quarter Beat, Upbeat Guidance
February 06, 2025
AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.
Via
Investor's Business Daily
AstraZeneca Q4 Earnings: Revenue And EPS Beat On Higher Cancer And Respiratory Drug Sales, Faces $4.5 Million Potential Fine In China
February 06, 2025
AstraZeneca's Q4 revenue beat estimates at $14.89 billion, with strong oncology sales. China sales dipped 1%, while FY25 guidance forecasts solid growth.
Via
Benzinga
Arcutis Soared In 2024, Blazing Trails In Dermatology. Why Its CEO Eyes Bigger Gains.
February 06, 2025
The company won three FDA approvals over the past two years. Now, it's angling for two new approvals in 2025.
Via
Investor's Business Daily
Exposures
Product Safety
AstraZeneca’s Full Year and Q4 2024 results
February 06, 2025
From
AstraZeneca
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.